Ntanasis-Stathopoulos, I.; Filippatos, C.; Gavriatopoulou, M.; Malandrakis, P.; Eleutherakis-Papaiakovou, E.; Spiliopoulou, V.; Syrigou, R.-E.; Theodorakakou, F.; Fotiou, D.; Migkou, M.;
et al. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era. Diseases 2023, 11, 123.
https://doi.org/10.3390/diseases11030123
AMA Style
Ntanasis-Stathopoulos I, Filippatos C, Gavriatopoulou M, Malandrakis P, Eleutherakis-Papaiakovou E, Spiliopoulou V, Syrigou R-E, Theodorakakou F, Fotiou D, Migkou M,
et al. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era. Diseases. 2023; 11(3):123.
https://doi.org/10.3390/diseases11030123
Chicago/Turabian Style
Ntanasis-Stathopoulos, Ioannis, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Rodanthi-Eleni Syrigou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou,
and et al. 2023. "Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era" Diseases 11, no. 3: 123.
https://doi.org/10.3390/diseases11030123
APA Style
Ntanasis-Stathopoulos, I., Filippatos, C., Gavriatopoulou, M., Malandrakis, P., Eleutherakis-Papaiakovou, E., Spiliopoulou, V., Syrigou, R.-E., Theodorakakou, F., Fotiou, D., Migkou, M., Roussou, M., Kastritis, E., Dimopoulos, M. A., & Terpos, E.
(2023). Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era. Diseases, 11(3), 123.
https://doi.org/10.3390/diseases11030123
